[Berofor alpha 2 (r-HUIFN-alpha 2 arg) and acyclovir in the treatment of dendritic keratitis].

Abstract

In a double-masked clinical trial a total of 24 patients have so far been treated with recombinant human alpha 2-interferon in combination with Acyclovir (ACV), and 21 patients with a placebo-Acyclovir combination. Both partial and complete healing times were statistically significantly shortened in the r-Hu IFN-alpha 2-AVC group, by 35 and 32 percent respectively. No difference could be demonstrated between the combination of r-Hu IFN-alpha 2 arg and ACV and that of BCL IFN and ACV as far as the therapeutic effect was concerned. R-Hu IFN-alpha 2 drops in combination with Acyclovir ointment were excellently tolerated.

• Authors: P J Meurs, O P van Bijsterveld
• Journal: Klinische Monatsblatter fur Augenheilkunde (Klin Monbl Augenheilkd) Vol. 187 Issue 1 Pg. 40-2 (Jul 1985) ISSN: 0023-2165 [Print] Germany
• Vernacular Title: Berofor Alpha 2 (r-Hu IFN-alpha 2 arg) und Aciclovir in der Behandlung der Herpes-Keratitis-dendritica.
• PMID: 3934457 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Interferon Type I
• Interferon-alpha
• Ointments
• Ophthalmic Solutions
• Recombinant Proteins
• Interferon-gamma
• interferon alfa-2c
• Acyclovir

Topics

• Acyclovir (administration & dosage, therapeutic use)
• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Humans
• Interferon Type I
• Interferon-alpha
• Interferon-gamma (administration & dosage)
• Keratitis, Dendritic (drug therapy)
• Male
• Middle Aged
• Ointments
• Ophthalmic Solutions
• Random Allocation
• Recombinant Proteins (administration & dosage)